María Obdulia
Rabal Gracia
Forscherin bis um 2019
Publikationen, an denen er mitarbeitet María Obdulia Rabal Gracia (9)
2019
-
Discovery of in Vivo Chemical Probes for Treating Alzheimer's Disease: Dual Phosphodiesterase 5 (PDE5) and Class i Histone Deacetylase Selective Inhibitors
ACS Chemical Neuroscience, Vol. 10, Núm. 3, pp. 1765-1782
-
Multitarget Approach for the Treatment of Alzheimer's Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) Covering Diverse Selectivity Profiles
ACS Chemical Neuroscience, Vol. 10, Núm. 9, pp. 4076-4101
-
Taking advantage of the selectivity of histone deacetylases and phosphodiesterase inhibitors to design better therapeutic strategies to treat Alzheimer's disease
Frontiers in Aging Neuroscience, Vol. 11, Núm. JUN
2018
-
Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease
European Journal of Medicinal Chemistry, Vol. 150, pp. 506-524
-
Immunomodulatory properties of carvone inhalation and its effects on contextual fear memory in mice
Frontiers in Immunology, Vol. 9, Núm. JAN
2017
-
A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice
Neuropsychopharmacology, Vol. 42, Núm. 2, pp. 524-539
-
Impact of Scaffold Exploration on Novel Dual-Acting Histone Deacetylases and Phosphodiesterase 5 Inhibitors for the Treatment of Alzheimer’s Disease
ACS Chemical Neuroscience, Vol. 8, Núm. 3, pp. 638-661
2016
-
Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease
Journal of Medicinal Chemistry, Vol. 59, Núm. 19, pp. 8967-9004